**Conditions for considerations of referral into a**

**Maternal Medicine Centre**

**Issue Date:** *10/09/2023* **Next Review Date:** *10/03/2026*

**1. Objective**

The Yorkshire and The Humber (Y&H) regions have come together to form The Y&H Maternal Medicine Network (MMN). The aim of the MMN is to provide equitable and expert care to women and birthing people with pre-existing or pregnancy induced medical conditions

The purpose of the document is to provide guidance to professionals regarding who to refer to the MMN.

 **2. Background**

The criteria for referral has been developed using the NHSE Maternal Medicine Service Specification (2020) as guidance, in consultation with Lead Obstetricians and Physicians at both Maternal Medicine Centres. There have been some amendments to reflect local expertise and capacity at both Maternal Medicine Centres at Leeds Teaching Hospitals Trust and Sheffield Teaching Hospitals.

The criteria for referral for cardiology has been developed in consultation with the Pregnancy Care Guideline for Women in Yorkshire & Humber Network with known Congenital Cardiac Disease (Yorkshire and Humber Congenital Heart Disease Operational Delivery Network 2021).

An update to the original document was added in September 2023 to reflect the requirements of Saving Babies Lives V3. In addition, minor alterations have been made to reflect the care of women with epilepsy and an addition to the cardiology referral criteria to now include heart transplant.

**3. Referral information**

For any conditions that are not included in this document that you require advice for/referral to a Maternal Medicine Centre, please email leedsth-tr.maternalmedicine@nhs.net for Leeds or sth.jessopwing.maternalmedicine@nhs.net if referring to Sheffield MMC. The Leeds Maternal Medicine Centre has 2 individual referring emails for both Cardiology and Haematology for direct referrals. The email addresses for these specialties are leedsth-tr.obscardiac@nhs.net and leedsth-tr.obshaem@nhs.net

When referring a patient, please take into consideration that those who are from an ethnic minority, have a severe mental illness or are socially deprived, are at higher risk of poor physical health and poor outcomes, compared with the general patient population. The perinatal period adds further complexity, therefore please ensure you consider mental health needs of the patient and refer to your local perinatal mental health service appropriately. The YH Mental Health Clinical Network website provides useful information and signposting: https://www.yhscn.nhs.uk/mental-health-clinical-network

**4. Definitions**

|  |
| --- |
| **Category A- Local Expertise -** Medical conditions that can be managed using local expertise and evidence based maternity care. |
| **Category B- Review, Advice and Guidance from Maternal Medicine Centre -** Complex medical conditions where a Maternal Medicine Centre provides clinical review (either virtually or face to face according to clinical need) and ongoing **advice and guidance** to local maternity unit. |
| **Category C- Care led by Maternal Medicine Centre -** Highly complex medical conditions where care in pregnancy is **led by the Maternal Medicine Centre** during pregnancy and includes plan for delivery. |

**Cardiology**

**Acquired Cardiac Disease**

|  |  |  |  |
| --- | --- | --- | --- |
| **Urgent referral to MMC** | **Care led by Maternal Medicine Centre** | **Review, advice & guidance from MMC** | **Local expertise** |
| * Pulmonary hypertension – refer to Sheffield
 | **Cardiomyopathies:** * Hypertrophic - Dilated or Previous or Peripartum
 | * ICD
 | * Common arrythmias\*
 |
| * Mod-Severely impaired left ventricular dysfunction
 |  **Channelopathies:*** Long QT
* Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
* Brugada
* Other
 | * Common arrythmias (where concerned)
 |  |
| * Heart Transplant
 |  | * Ischaemic heart disease (stable)
 |  |
|  |  | * Acute coronary syndrome
 |  |
|  |  | * SCAD
 |  |
|  |  | * Previous Cardio toxic chemotherapy with abnormal 1st or 3rd trimester echo
 |  |

**\* Should be reviewed by local Obstetric and Cardiology teams. Refer after local Cardiology review if required**

**Congenital Heart Disease**

|  |  |  |  |
| --- | --- | --- | --- |
| **Urgent referral to MMC** | **Care led by Maternal Medicine Centre** | **Review, advice & guidance from MMC** | **Local expertise** |
| * BAV with aortopathy or Turner’s syndrome with max aortic root/ascending aorta diameter ≥45mm ng aorta diameter ≥45mm
 | * Severe aortic or mitral regurgitation
 | * Mild-moderate aortic /mitral regurgitation
 | * Repaired ASD/ VSD\*\*
 |
| * Marfan’s syndrome or other CTD\* with dilated aortic root
 | * Severe pulmonary stenosis Moderate or severe aortic stenosis
 | * Severe Pulmonary regurgitation
 | * Repaired Patent Ductus Arteriosus\*\*
 |
| * Severe systemic ventricular impairment
 | * Moderate or severe mitral stenosis Coarctation of aorta, native, operated or intervened on
 | * Moderate aortic stenosis (Pre-pregnancy peak gradient <50mmHg)
 |  |
| * Mechanical (metal) valve
 | * TGA repair: Mustard/Senning, Arterial switch (not good function/quality)
 | * TGA repair: good quality/function arterial switch
 |  |
| \*Ehlers-Danlos Type 4, Loeys-Dietz, Familial Thoracic Aortic Aneurysm and Dissection syndrome or high suspicion of unidentified cause | * Fontan circulation
 | * Mild mitral stenosis
 |  |
|  | * Cyanotic heart disease without pulmonary hypertension
 | * Unrepaired ASD
 |  |
|  | * Bicuspid Aortic Valve (BAV)with aortopathy or Turner’s syndrome with maximum aortic root/ascending aorta
 | * Tetralogy of Fallot
 |  |
|  |  | * Repaired Fallot’s Tetralogy
 |  |
|  |  | * Restrictive VSD (unrepaired)
 |  |
|  |  | * Repaired ASD/VSD with ongoing congenital cardiology follow up
 |  |
|  |  | * Isolated Patent Ductus Arteriosus (without pulmonary hypertension) with ongoing congenital cardiology input
 |  |
|  |  | * Repaired total anomalous pulmonary venous drainage
 |  |
|  |  | * Bicuspid aortic valve; no aortopathy
 |  |
|  |  | * Mild aortic stenosis Mild/moderate pulmonary stenosis / regurgitation
 |  |

**\* Should be reviewed by local Obstetric and Cardiology teams. Refer after local Cardiology review if required**

**\*\* Can be managed locally if discharged from congenital cardiology input**

**Diabetes and Endocrine**

|  |  |  |
| --- | --- | --- |
| **Care led by Maternal Medicine Centre** | **Review, advice & guidance from MMC** | **Local expertise** |
| * Pheochromocytoma
 | * Uncontrolled hyperthyroidism
 | * Hyperthyroidism – well controlled
 |
| * Cushing’s syndrome
 | * Adrenal tumours
 | * Hypothyroidism
 |
| * Acromegaly
 | * Congenital adrenal hyperplasia
 | * Thyroid nodules
 |
| * Metabolic disorders
 | * Addison’s disease
 | * Microprolactinoma
 |
| * Hyperparathyroidism with raised calcium
 | * Hypopituitarism
 | * Type 1/ 2 diabetes
 |
|  | * Thyroid Cancer
 |  |
|  | * Macroprolactinoma
 |  |
|  | * Type 1 diabetes with autonomic neuropathy
 |  |
|  | * Monogenic diabetes
 |  |
|  | * CVD
 |  |
|  | * Type 1/ 2 diabetes with retinopathy requiring treatment during pregnancy
 |  |
|  | * Type 1/ 2 diabetes with renal impairment:

\*CKD 2 with significant proteinuria i.e. PCR>30 at booking* \*CKD 3
 |  |
|  |  |  |

**Haematology**

|  |  |  |
| --- | --- | --- |
| **Care led by Maternal Medicine Centre** | **Review, advice & guidance from MMC** | **Local expertise** |
| * Fetus affected by moderate to severe haemophilia (or not known whether fetus affected)
* Carrier of haemophilia with low levels Factor VIII/IX
 | * Haemophilia carrier (refer carriers of haemophilia as early as possible)
* Partner of pregnant patient with Haemophilia A/B
 | * Gestational thrombocytopenia
* Historical ITP and platelets >75
 |
| * Type 2 & 3 VWD
* Type 1 VWD if VWF not normalised
 | * Type 1 VWD: VWF normalised in pregnancy
 | * Inherited thrombophilia (no previous VTE, not antithrombin deficiency)
 |
| * Any bleeding disorder already under care in MMC, or likely to require haemostatic support antenatally or peripartum to reduce haemorrhage risk (including severe platelet disorders)
 | * Mild bleeding disorder, or partner of patient with mild bleeding disorder (platelet function defect, other mild coagulation factor deficiency such as Factor XI deficiency)
 | * Obstetric antiphospholipid syndrome
 |
| * Antithrombin deficiency
 | * Current ITP and platelets <75
 | * Current or previous VTE event
 |
| * Thrombotic Antiphospholipid Syndrome
 | * Inherited thrombophilia with previous VTE
 | * Sickle cell trait
 |
| * Sickle cell disease
 | * Current extensive VTE or new VTE > 36/40 gestation
 | * Alpha/beta thalassaemia trait
 |
| * Transfusion Dependent Thalassaemia
 | * Rarer red cell disorders already under MMC care
 | * Previous treated haematological malignancy
 |
| * Active haematological malignancy
 | * Non-transfusion dependent thalassaemia
* Thalassaemia trait and Hb <75
 | * Thrombocytosis
 |
| * TTP requiring treatment
 | * Myeloproliferative disorders
 |  |
| * PNH
 | * TTP in remission
 |  |

**Gastroenterology**

|  |  |  |
| --- | --- | --- |
| **Care led by Maternal Medicine Centre** | **Review, advice & guidance from MMC** | **Local expertise** |
| * Complex pancreatitis
 | * Complex IBD (Incl perianal disease/pouch/stoma)
 | * Uncomplicated IBD
 |
| * Hypertriglyceridemia
 | * Acute and chronic pancreatitis
 | * Active IBD controlled on steroids /biologics (Should be reviewed by local Obstetric and Gastro team. Refer after local review if required)
 |
| * Active GI malignancy
 | * Treated GI malignancy
 |  |

**Hepatology**

|  |  |  |
| --- | --- | --- |
| **Care led by Maternal Medicine Centre** | **Review, advice & guidance from MMC** | **Local expertise** |
| * Any degree of portal hypertension
 | * Autoimmune hepatitis
 | * viral hepatitis**\***
 |
| * Decompensating Liver disease
 | * Crigler Najjar syndrome
 |  |
| * Cirrhosis
 | * Wilson's disease
 |  |
| * Liver Transplant
 | * Primary sclerosing cholangitis
 |  |
|  | * Primary biliary cholangitis
 |  |

**\*Should be reviewed by local Obstetric and Hepatology team. Refer after local review if required.**

**Infectious Diseases**

|  |  |  |
| --- | --- | --- |
| **Care led by Maternal Medicine Centre** | **Review, advice & guidance from MMC** | **Local expertise** |
|  | * Malaria
 | * HIV
 |

**Neurology**

| **Care led by Maternal Medicine Centre** | **Review, advice & guidance from MMC** | **Local expertise** |
| --- | --- | --- |
| * New diagnosis/ flare up of Myasthenia gravis
 | * Unstable Multiple Sclerosis or on disease modifying drugs
 | * Previous ischaemic stroke
 |
| * Acute Stroke
 | * Untreated intracranial aneurysm
 | * Epilepsy \*
 |
| * Progressive brain Tumour
 | * Previous intracranial haemorrhage
 | * Previous CVT
 |
| * Unstable CVM/ AVM/cavernoma/ intracerebral bleed within 2 years
 | * Complex or poorly controlled epilepsy on multiple AEDs
 | * Meningitis /encephalitis \*
 |
| * New onset Guillian barre syndrome
 | * Stable CVM/AVM/Cavernoma
 | * Idiopathic intracranial hypertension
 |
|  | * Current stable brain tumour
 | * Stable MS without disease modifying drugs \*
 |
|  | * New CVT
 |  |
|  | * Previous Guillian Barre syndrome
 |  |
|  | * Stable Myasthenia Gravis
 |  |
|  | * Spinal cord injury
 |  |
|  | * Spinal Muscular Atrophy
 |  |
|  | * MND
 |  |
|  | * Symptomatic raised intracranial pressure
 |  |
|  | * Myotonic dystrophy
 |  |

**\* Should be reviewed by the local obstetric and neurology teams. Refer after local review if required or if no local neurology input.**

**Renal**

| **Care led by Maternal Medicine Centre** | **Review, advice & guidance from MMC** | **Local expertise** |
| --- | --- | --- |
| * CKD 5
 | * CKD 3-4
 | * CKD 1-2
 |
| * Combined kidney pancreas transplant
 | * GN on maintenance immunotherapy
 | * AD polycystic kidney disease with normal renal function
 |
| * New renal vasculitis
 | * Lupus nephritis (stable)
 |  |
| * Active/ Unstable Lupus nephritis
 | * Autosomal dominant polycystic kidney disease (ADPKD)
 |  |
| * Scleroderma renal crisis
 | * Renal dialysis
 |  |
|  | * Reflux nephropathy and congenital abnormality of kidney and urinary tract with CKD stage 3-4
 |  |
|  | * Renal Transplant
 |  |
|  | Type 1/2 Diabetes with CKD 2 and significant proteinuria i.e. PCR>30 at booking |  |

**Respiratory**

| **Care led by Maternal Medicine Centre** | **Review, advice & guidance from MMC** |  **Local expertise** |
| --- | --- | --- |
| * Cystic Fibrosis
 | * Restrictive lung disease (e.g. ILD)
 | * Asthma
 |
| * Lung Transplant
 | * Any pulmonary condition currently receiving immunotherapy
 |  |
| * Pulmonary Hypertension
 |  |  |

**Rheumatology**

| **Care led by Maternal Medicine Centre** | **Review, advice & guidance from MMC** | **Local expertise** |
| --- | --- | --- |
| * Scleroderma
 | * Any CTD with evidence of extra-articular manifestations involving heart, lungs or kidneys
 | * Stable inflammatory arthritis on pregnancy appropriate treatment
 |
| * Vascular/Type IV Ehlers Danlos Syndrome
 | * SLE with renal, cardiac or cerebral involvement
 | * Stable CTD not on biologics
 |
|  | * Vasculitis (anti-GBM or ANCA positive)
 | * Hypermobile Ehlers Danlos type 3
 |
|  | * Sjogren’s syndrome with Ro antibody positivity
 |  |
|  | * Other Ehlers Danlos syndrome
 |  |

**Miscellaneous**

| **Care led by Maternal Medicine Centre** | **Review, advice & guidance from MMC** | **Local expertise** |
| --- | --- | --- |
|  | * Cancer
 | * Polymorphic Eruption of Pregnancy
 |
|  | * Acute illness where the underlying condition is not clear: headache, breathlessness, chest pain, abdominal pain, fever/sepsis
 |  |
|  | * Skin Disease e.g. Pemphigoid Gestationis
 |  |

**5. Declarations of Interests**

No declaration of interest.

 **6. References**

Maternal Medicine Service Specification (2021)

NHSE 13th October 2021, version 1

Pregnancy Care Guideline for Women in Yorkshire & Humber Network with known Congenital Cardiac Disease (2021)

Yorkshire and Humber Congenital Heart Disease Operational Delivery Network

**7. Contributors**

***The following Obstetric and Medical leads have been consulted by Dr Tessa Bonnett and Dr Medha Rathod during the development of this document:***

|  |  |
| --- | --- |
| **Obstetricians:**Dr Tessa BonnettDr Gemma GovindenDr Victoria SternDr Yash ChoudharyMr Roobin JohkiDr Shehnaaz JivrajDr Priya MadhuvrataDr Samantha LoweDr Hannah YeelesDr Etienne CianterDr Thomas Everett Dr Medha RathodDr Tracy GlanvilleDr Jayne Shilito | **Physicians:**Dr Laurence O’TooleProfessor Tim ChicoDr Emma WalkinshawDr Siew WongDr Kar-Ping KuetDr Mohammed AkilDr Rachel KildingDr Josh ChewDr Giorgia SacculloDr Rhona MacleanDr Clare SamuelsonDr Ida PernacovaDr William BennetDr Veena ReddyDr Ana GarciaDr Alex SimmsDr Kate EnglishDr Kate GatenbyDr Christian SelingerDr Shovik DassDr Ana SwainDr Jayne DillonProfessor Helen FordJo Geldard (epilepsy nurse) |

**8.Target Professional Group**

All professionals caring for women with complex medical conditions.

|  |
| --- |
| **Document Control** |
| **Name:**  | Conditions for consideration for referral into the Y&H MMN  | **First published:** | March 2023 |
| **Version:** | V1 | **Current Version Published:** | March 2023 |
| **Ratification Committee:** | Leeds Teaching Hospitals, Women’s Clinical Support Group Quality Assurance Group | **Review Date:** | March 2026 |
| **Document Managed by****Name:** | Debbie Scott | **Document Managed by Title:** | Consultant Midwife MMN |
| **Consultation Process** |
| Y&H Maternal Medicine Network, ratified at Leeds Teaching Hospitals, Women’s Clinical Support Group Quality Assurance Group Meeting March 2023 |
|   | **Version Control** |   |
|   | **Date** | **Version** | **Contributor** | **Revision description** |   |
|   | March 2023 | V1 | As above | New policy  |   |
|  | September 2023 | V1.1 | As above | To reflect SBLv3 |  |
|  |  |  |  |  |  |  |  |  |  |  |